Alternatives to the use of estrogen in postmenopausal women

Endocrine Reviews

Volumn 20, Issue 3, 1999, Pages 308-320

  Pinkerton, J V ^a   Santen, R ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALPHA TOCOPHEROL; ANTIESTROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLONIDINE; CONJUGATED ESTROGEN; ESTROGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MEVINOLIN; RALOXIFENE; REPLENS; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; TAMOXIFEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

BONE DENSITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FRACTURE; HEART PROTECTION; HERBAL MEDICINE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; UROGENITAL TRACT DISEASE;

EID: 0033305452     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.20.3.0369     Document Type: Review

References (128)

1. Consensus statement: Treatment of estrogen deficiency symptoms in women surviving breast cancer
2. Treatment of estrogen deficiency symptoms in women surviving breast cancer
3. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
4. Estrogen replacement and coronary artery disease: Effect on survival in postmenopausal women
5. Decreased mortality in users of estrogen replacement therapy
6. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: Evidence from a national cohort
7. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
8. Hormone therapy to prevent disease and prolong life in postmenopausal women
9. The epidemiology of coronary artery disease and estrogen replacement in postmenopausal women
10. Clinical review: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women
11. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
12. Hormone replacement therapy and coronary artery atherosclerosis: The monkey model
13. Mechanisms of cardiovascular protection by post-menopausal hormone replacement therapy
14. Effects of postmenopausal hormone replacement therapy with oral and transdermal estrogen on high density lipoprotein metabolism
15. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
16. Cardiovascular Disease in women: A statement for health care professionals from the American Heart Association
17. Relative vs. attributable risk of breast cancer from estrogen replacement therapy
18. Postmenopausal estrogen and prevention bias
19. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies?
20. Prior to use of estrogen replacement therapy, are users healthier than nonusers?
21. Evidence of a healthy estrogen user effect
22. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
23. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women
24. HDL cholesterol as a predictor of cardiovascular mortality in men and women: The followup study of the Lipid Research Clinics Prevalence Study
25. Plasma lipoprotein levels as predictors of cardiovascular death in women
26. Prevention of coronary heart disease through cholesterol reduction
27. Effects of lipid-lowering therapy on total and coronary mortality
28. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
29. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)
30. Atherogenicity of lipoprotein(a): The debate
31. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group
32. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
33. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 6 years of treatment
34. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial
35. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women
36. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
37. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits
38. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
39. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
40. Lack of effect of Raloxifene on coronary artery atherosclerosis of postmenopausal monkeys
41. Clinical Review 92. Phytoestrogens
42. Cancers of the Prostate and breast among Japanese and white immigrants in Los Angeles County
43. A Large scale cohort study on cancer risks by diet-with special reference to the risk reducing effects of green-yellow vegetable consumption
44. Dietary effects on breast-cancer risk in Singapore
45. Western diet and western diseases: Some hormonal and biochemical mechanisms and associations
46. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis
47. Soy protein vs. soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys
48. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys
49. The potential of soybean phytoestrogens for postmenopausal hormone replacement therapy
50. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques
51. Meta-analysis of the effects of soy protein intake on serum lipids
52. Isoflavones from Red Clover improve systemic arterial compliance but not plasma lipids in menopausal women
53. Atherosclerosis and estrogen replacement therapy
54. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women
55. Postmenopausal hormone therapy and mortality
56. Estrogen replacement and coronary artery disease: Effect on survival in postmenopausal women
57. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
58. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys
59. Effect on Survival of estrogen replacement therapy after coronary artery bypass grafting
60. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions
61. Current estrogen-progestin and estrogen replacement therapy in elderly women: Association with carotid atherosclerosis. CHS Collaborative Research Group. Cardiovascular Health Study
62. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
63. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
64. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
65. A two-year program of aerobics and weight training enhances bone mineral density of young women
66. Exercise effects on bone mass in postmenopausal women are site-specific and load dependent
67. The effect of calcium supplementation on the circadian rhythm of bone resorption
68. Drug therapy: Treatment of postmenopausal osteoporosis
69. Effects of hormone replacement therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
70. The waning effect of postmenopausal estrogen therapy on osteoporosis
71. Therapeutic controversy: Estrogen replacement in menopause
72. Estrogen replacement and fractures in older women: Study of Osteoporosis Fractures Research Group
73. The effect of post menopausal estrogen therapy on bone density in elderly women
74. Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group
75. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium
76. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study
77. Hip fracture and the use of estrogen in postmenopausal women. The Framingham Study
78. Fracture protection provided by long-term estrogen treatment
79. Menopausal estrogen therapy and hip fractures
80. Treatment of postmenopausal osteoporosis with transdermal estrogen
81. The effect of tamoxifen on the endometrium
82. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group
83. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
84. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers
85. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group
86. Treatment with alendronate prevents fractures in women at highest risk: Results from the Fracture Intervention Trial
87. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial
88. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss
89. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis
90. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
91. Salmon-calcitonin nasal spray prevents vertebral fractures in established osteoporosis. Further interim results of the PROOF study. European Congress on Osteoporosis
92. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in health premenopausal and postmenopausal women
93. Raloxifene reduces the risk of incident vertebral fractures: 24 Month interim analysis
94. Osteoporosis: Trials and Tribulations
95. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer
96. Comparative study: Replens vs. local estrogen in menopausal women
97. Vaginal administration of low-dose conjugated estrogens: Systemic absorption and effects on the endometrium
98. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy
99. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging
100. Treatment of urogenital atrophy
101. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors
102. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes
103. Effect of clonidine on hot flashes in postmenopausal women
104. Megestrol acetate for the prevention of hot flashes
105. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
106. Hormone therapy and phytoestrogens
107. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial
108. The role of estrogen in the treatment of Alzheimer's disease
109. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
110. Gender, oestrogen, hormone replacement and age-related macular degeneration: Results from the Blue Mountains Eye Study
111. Postmenopausal hormone use and risk for colorectal cancer and adenoma
112. The benefits of estrogen replacement therapy on oral health
113. The effects of estrogen and osteoarthritis
114. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
115. Risk of venous thromboembolism in users of hormone replacement therapy
116. Increased risk of cholecystectomy in users of supplemental estrogen
117. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysical and biochemical study
118. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
119. Esophagitis associated with the use of alendronate
120. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis
121. Use of calcitonin in the treatment of bone pain associated with osteoporosis
122. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer. Two year findings from Multiple Outcomes of Raloxifene Trial
123. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes
124. What pharmacists should know about herbal remedies
125. Herbal hepatotoxicity: Revisiting a dangerous alternative
126. Chaparral-associated hepatotoxicity